Performance of Different Amyloid Immunoassays in Predicting Outcome of Visual Assessment of Amyloid PET Imaging

2017

JAMA Neurology (in press).

Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.

2025 The CentiMarker project: Standardizing quantitative Alzheimer’s disease fluid biomarkers for biologic interpretation.
2025 Associations between the EAT-Lancet planetary health diet and incident dementia.
2025 Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
2025 Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease.
2025 Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
2025 The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus.
2025 Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer’s disease.
2025 Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data
2025 Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.
2025 Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice.
2025 The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
2025 Toward a biological definition of neuronal and glial synucleinopathies.
2025 Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
2025 Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum.